Molika Ashford

The technology, developed by researchers at Stanford, showed strong performance in a new study of lymphoma, and early data for solid tumors is already available.

Investigators analyzed blood samples from patients at two time points after curative-intent surgery, finding that ctDNA MRD status was highly predictive of outcome.

The firm announced the new test, Guardant360 Response, alongside its launch of its Guardant360 TissueNext tumor tissue genomic profiling product.

A new publication detailing ctDNA testing results has spurred a minimal residual disease biomarker-directed trial for Roche's atezolizumab in bladder cancer.

Research presented at the ASCO meeting described efforts to expand the use of existing technologies into new directions.

The first interventional trial to use ctDNA to recruit eligible patients for this treatment showed 30 percent observable responses and more than 60 percent disease control.

The company presented its first analyses answering crucial questions about real-world performance and impact on patients' well-being and healthcare utilization.

The company expects to launch testing for advanced cancer patients this year, with studies now running to expand to cancer screening and monitoring applications.

The data, while limited, indicate that the firm's blood-only assay may be able to match the performance of existing commercial tissue-informed competitors.

The firm continues to pursue new applications for its multiomics machine learning technology, with recent data exploring immunotherapy response prediction.